Ernexa Director Cherington Charles Buys 4 Million Shares in Follow‑On, Betting on Upcoming Phase‑1 Results
Insider buying in Ernexa’s follow‑on offering signals confidence in the Phase‑1 mRNA data and could lift valuation, but investors should watch clinical milestones closely.
3 minutes to read